IP Library › Granted Patent US 10,548,957
Granted Patent B2
US 10,548,957 · App. 14/431,113 · Granted Feb 4, 2020

Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis

Inventors: Harvey Cantor (Boston, MA); Hye-Jung Kim (Brookline, MA); Jianmei Wu Leavenworth (Hoover, AL)
Assignee: Dana-Farber Cancer Institute, Inc.
A61K39/0008A61K35/17C07K14/47C07K14/70539C12N5/0636A61K2039/5154A61K2039/5158A61K2039/58C12N2501/2315
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,548,957
App. No.
14/431,113
Granted
Feb 4, 2020
Kind
B2
Abstract

Nanoparticles to treat autoimmune diseases and HIV infection are provided. The nanoparticles comprise a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle. The present invention also relates to methods for treating autoimmune diseases and HIV infection.

Claims (5)

1. A nanoparticle comprising a biocompatible polymer and a complex, wherein the complex is a major histocompatibility complex (MHC) class I antigen E (HLA-E) linked to a peptide, and wherein the HLA-E-peptide complex is linked to the surface of the nanoparticle, and wherein the peptide is Hsp60p216 or FL9.

2. The nanoparticle of claim 1 , wherein at least 4 units, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 units of the HLA-E-peptide complex are linked together to form a moiety and the moiety is linked to the surface of the nanoparticle.

3. The nanoparticle of claim 1 , wherein the peptide is linked to the HLA-E via a flexible linker.

4. The nanoparticle of claim 1 , wherein heavy chain and light chain (β-2 microglobulin) of the HLA-E are linked via a flexible linker.

5. The nanoparticle of claim 1 , wherein a low releasing dose of IL-15 is incorporated into the nanoparticle.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 19, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039389/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2015
From: CANTOR, HARVEY; KIM, HYE-JUNG; LEAVENWORTH, JIANMEI WU
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 036134/0394 →
Continuity (3)
Provisional Application 61773959 · Mar 7, 2013
Provisional Application 61707357 · Sep 28, 2012
Related Publication 20150250862A1 · Sep 10, 2015